Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Other Accumulated Expenses (2016 - 2026)

Mimedx's Other Accumulated Expenses history spans 16 years, with the latest figure at $6.1 million for Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses rose 36.51% to $6.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.1 million, a 36.51% increase, with the full-year FY2025 number at $5.8 million, up 28.47% from a year prior.
  • Other Accumulated Expenses hit $6.1 million in Q1 2026 for Mimedx, up from $5.8 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for MDXG hit a ceiling of $6.1 million in Q1 2026 and a floor of $1.6 million in Q1 2022.
  • Historically, Other Accumulated Expenses has averaged $3.1 million across 5 years, with a median of $2.6 million in 2024.
  • Biggest five-year swings in Other Accumulated Expenses: decreased 6.04% in 2022 and later soared 126.92% in 2024.
  • Tracing MDXG's Other Accumulated Expenses over 5 years: stood at $1.8 million in 2022, then surged by 57.8% to $2.9 million in 2023, then soared by 55.74% to $4.5 million in 2024, then increased by 28.47% to $5.8 million in 2025, then increased by 4.56% to $6.1 million in 2026.
  • Business Quant data shows Other Accumulated Expenses for MDXG at $6.1 million in Q1 2026, $5.8 million in Q4 2025, and $4.4 million in Q3 2025.